65LAB is a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund, as well as global life science company Evotec, set up to drive scientific advancement and create new biotech ventures from Singapore.
65LAB identifies promising innovation in partner research institutions -- A*STAR, Duke-NUS Medical School and National University of Singapore -- and provides targeted funding and industry expertise to evolve this academic research into new therapeutic companies.
Read More65LAB is a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund, as well as global life science company Evotec, set up to drive scientific advancement and create new biotech ventures from Singapore.
65LAB identifies promising innovation in partner research institutions -- A*STAR, Duke-NUS Medical School and National University of Singapore -- and provides targeted funding and industry expertise to evolve this academic research into new therapeutic companies.
A tripartite strategic collaboration with Biosparc, ClavystBio and True Light PE. Together, the partners aim to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization within the park. By leveraging each party’s networks and capabilities, the partnership will strengthen cross-border R&D and establish a sustained pipeline for project landing and growth.
Biosparc is a life sciences industrial park developed through a partnership between Temasek and Suzhou Industrial Park (SIP). It focuses on advancing cutting-edge innovations in drug development, medical devices, life science tools, digital healthcare solutions, and AI-driven medical technologies.
Located on Sangtian Science Island in SIP, Biosparc leverages the region's robust industrial base and diversified resources from its international stakeholders. It offers world-class R&D facilities and comprehensive, integrated services to support the growth of enterprises throughout their lifecycle.
Biosparc is dedicated to fostering research and industrial collaboration between China and Singapore, connecting global resources, deepening international partnerships, and empowering a global life sciences innovation ecosystem.
The park is currently under construction and is expected to launch in 2026.
For more information, please visit Biosparc’s WeChat channel (account name: Biosparc).
Read MoreA tripartite strategic collaboration with Biosparc, ClavystBio and True Light PE. Together, the partners aim to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization within the park. By leveraging each party’s networks and capabilities, the partnership will strengthen cross-border R&D and establish a sustained pipeline for project landing and growth.
Biosparc is a life sciences industrial park developed through a partnership between Temasek and Suzhou Industrial Park (SIP). It focuses on advancing cutting-edge innovations in drug development, medical devices, life science tools, digital healthcare solutions, and AI-driven medical technologies.
Located on Sangtian Science Island in SIP, Biosparc leverages the region's robust industrial base and diversified resources from its international stakeholders. It offers world-class R&D facilities and comprehensive, integrated services to support the growth of enterprises throughout their lifecycle.
Biosparc is dedicated to fostering research and industrial collaboration between China and Singapore, connecting global resources, deepening international partnerships, and empowering a global life sciences innovation ecosystem.
The park is currently under construction and is expected to launch in 2026.
For more information, please visit Biosparc’s WeChat channel (account name: Biosparc).
ClavystBio and DxD Hub are collaborating to accelerate diagnostics and digital health ventures.
Diagnostics Development Hub (DxD Hub) is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub drives the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption.
DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation.
ClavystBio and DxD Hub are collaborating to accelerate diagnostics and digital health ventures.
Diagnostics Development Hub (DxD Hub) is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub drives the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption.
DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation.
MedTech Catapult and ClavystBio will jointly identify and venture build new MedTech companies.
MedTech Catapult is a national initiative, hosted by Singapore’s Agency for Science, Technology and Research (A*STAR), dedicated to accelerating the productisation of high-value life science instruments and regulated medical devices in Singapore.
MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations.
To support long-term sector growth, MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore’s MedTech value chain.
Read MoreMedTech Catapult and ClavystBio will jointly identify and venture build new MedTech companies.
MedTech Catapult is a national initiative, hosted by Singapore’s Agency for Science, Technology and Research (A*STAR), dedicated to accelerating the productisation of high-value life science instruments and regulated medical devices in Singapore.
MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations.
To support long-term sector growth, MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore’s MedTech value chain.
ClavystBio partners NATi to accelerate the development of nucleic acid therapeutics
The Nucleic Acid Therapeutics Initiative (NATi) is a national platform hosted by the Agency for Science, Technology and Research (A*STAR) with the mission to build Singapore as the regional hub and model of excellence for research, clinical translation, and commercialisation of nucleic acid therapeutics (NAT) with built-in preparedness and resilience against future epidemics.
Read MoreClavystBio partners NATi to accelerate the development of nucleic acid therapeutics
The Nucleic Acid Therapeutics Initiative (NATi) is a national platform hosted by the Agency for Science, Technology and Research (A*STAR) with the mission to build Singapore as the regional hub and model of excellence for research, clinical translation, and commercialisation of nucleic acid therapeutics (NAT) with built-in preparedness and resilience against future epidemics.
ClavystBio is a partner of NHIC's Clinical Advancement and Development for Research, Entrepreneurship and Enterprise (CADRE) programme
The National Health Innovation Centre Singapore (NHIC) is a nationally appointed programme office that works with Public Health Institutions across Singapore to identify and commercialize promising clinical innovations.
ClavystBio works with NHIC to support healthtech projects with Public Healthcare Clusters/ Institutions in the early stages of the HealthTech commercialization journey. This includes areas such as venture co-creation, technology development, co-investment and nurturing of tri-competent healthtech talent.
Read MoreClavystBio is a partner of NHIC's Clinical Advancement and Development for Research, Entrepreneurship and Enterprise (CADRE) programme
The National Health Innovation Centre Singapore (NHIC) is a nationally appointed programme office that works with Public Health Institutions across Singapore to identify and commercialize promising clinical innovations.
ClavystBio works with NHIC to support healthtech projects with Public Healthcare Clusters/ Institutions in the early stages of the HealthTech commercialization journey. This includes areas such as venture co-creation, technology development, co-investment and nurturing of tri-competent healthtech talent.
SEEDS Capital and ClavystBio are co-investment partners.
As the investment arm of Enterprise Singapore, SEEDS Capital catalyses smart investments into innovative Singapore-based early-stage startups with strong intellectual content and global market potential.
SEEDS Capital adopts a co-investment model, working hand in hand with institutional investors from around the world. Leveraging our collective expertise and networks, we help startups commercialise, realise their business development plans and expand globally.
Read MoreSEEDS Capital and ClavystBio are co-investment partners.
As the investment arm of Enterprise Singapore, SEEDS Capital catalyses smart investments into innovative Singapore-based early-stage startups with strong intellectual content and global market potential.
SEEDS Capital adopts a co-investment model, working hand in hand with institutional investors from around the world. Leveraging our collective expertise and networks, we help startups commercialise, realise their business development plans and expand globally.
A tripartite strategic collaboration with Biosparc, ClavystBio and True Light PE. Together, the partners aim to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization within the park. By leveraging each party’s networks and capabilities, the partnership will strengthen cross-border R&D and establish a sustained pipeline for project landing and growth.
True Light (Shanghai) Private Equity invests in innovative, high-growth businesses in Greater China. It is a subsidiary of True Light Capital and is registered with the Asset Management Association of China. True Light Capital is an asset manager headquartered in Singapore and currently has assets under management of ~US$4b from global investors. It manages funds that are focused on investing in high-quality investment opportunities which have a nexus to or have a major business relationship with Greater China.
Read MoreA tripartite strategic collaboration with Biosparc, ClavystBio and True Light PE. Together, the partners aim to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization within the park. By leveraging each party’s networks and capabilities, the partnership will strengthen cross-border R&D and establish a sustained pipeline for project landing and growth.
True Light (Shanghai) Private Equity invests in innovative, high-growth businesses in Greater China. It is a subsidiary of True Light Capital and is registered with the Asset Management Association of China. True Light Capital is an asset manager headquartered in Singapore and currently has assets under management of ~US$4b from global investors. It manages funds that are focused on investing in high-quality investment opportunities which have a nexus to or have a major business relationship with Greater China.